Rugo Hope S
Breast Oncology Clinical Trials Program, University of California, San Francisco Comprehensive Cancer Center, 1600 Divisidero Street, 2nd Floor, San Francisco, CA 94115, USA.
Hematol Oncol Clin North Am. 2007 Apr;21(2):273-91. doi: 10.1016/j.hoc.2007.03.007.
Hormonal therapy for advanced breast cancer has evolved significantly in the more than 100 years since the first publications documenting the effect of ovarian ablation on advanced breast cancer in premenopausal women. Since that time, not only have we developed the methods to measure estrogen and progesterone receptors in cancer cells, but more recently we have understood that expression of these receptors determines response to hormone therapy. The availability of more selective antiestrogen therapies has changed and significantly improved the treatment options for women who have advanced hormone-responsive breast cancer. Current research is focusing on reversing resistance to hormone therapy with the addition of targeted biologic agents to standard hormonal treatment.
自首次发表文献记录卵巢切除对绝经前女性晚期乳腺癌的疗效以来，100多年间晚期乳腺癌的激素治疗有了显著进展。从那时起，我们不仅开发出了测量癌细胞中雌激素和孕激素受体的方法，而且最近我们还了解到这些受体的表达决定了对激素治疗的反应。更具选择性的抗雌激素疗法的出现改变并显著改善了晚期激素反应性乳腺癌女性的治疗选择。目前的研究集中在通过在标准激素治疗中添加靶向生物制剂来逆转对激素治疗的耐药性。
